FY2025 Earnings Forecast for PVLA Issued By Chardan Capital

Palvella Therapeutics (NASDAQ:PVLA) – Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for Palvella Therapeutics in a report released on Wednesday, April 9th. Chardan Capital analyst G. Livshits forecasts that the company will post earnings per share of ($2.43) for the year. Chardan Capital has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for Palvella Therapeutics’ FY2026 earnings at ($3.06) EPS.

A number of other equities analysts also recently weighed in on PVLA. TD Cowen started coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price on the stock. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target for the company. Cantor Fitzgerald began coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They issued an “overweight” rating for the company. Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, Jones Trading started coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $45.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $44.43.

Palvella Therapeutics Stock Performance

PVLA opened at $23.93 on Monday. The business’s fifty day moving average price is $22.94. The firm has a market capitalization of $263.68 million, a PE ratio of -1.98 and a beta of 0.10. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27.

Insider Activity at Palvella Therapeutics

In related news, Director George M. Jenkins bought 2,500 shares of the stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $20.13 per share, with a total value of $50,325.00. Following the completion of the purchase, the director now directly owns 183,171 shares in the company, valued at $3,687,232.23. This represents a 1.38 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 6.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PVLA. BML Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $506,000. ADAR1 Capital Management LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth about $1,736,000. Frazier Life Sciences Management L.P. acquired a new position in Palvella Therapeutics during the 4th quarter worth $7,847,000. Cresset Asset Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter valued at approximately $251,000. Finally, Suvretta Capital Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter valued at about $8,574,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.